|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
53142567
???header.onlineuser??? :
824
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"lakatos g"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
|
Chen, LT;Mercade, TM;Lee, KH;Lakatos, G;Wang-Gillam, A;Mirakhur, B;de Jong, F |
| 國家衛生研究院 |
2018-06 |
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
|
Lakatos, G;Lee, K;Siveke, J;Blanc, J;Mercade, TM;Dean, A;Bodoky, G;Mirakhur, B;Chen, J;Wang-Gillam, A;Chen, L;de Jong, F |
| 國家衛生研究院 |
2018-06 |
Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial
|
Mercade, TM;Lee, K;Lakatos, G;Wang-Gillam, A;Chen, L;Mirakhur, B;De Jong, F |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
